Washington D.C. – President Donald Trump on May 2, 2025, unveiled his administration’s discretionary budget request for Fiscal Year 2026, proposing substantial reductions in funding for key federal health agencies. The proposal, which sets the stage for upcoming fiscal negotiations, recommends allocating $93.8 billion to the Department of Health and Human Services (HHS), marking a notable 26.2 percent decrease from the funding levels approved for FY 2025. This request arrives as budget reconciliation negotiations continue in the House of Representatives, signaling a potentially contentious path forward for federal spending.
The proposed budget cuts span various critical health-focused entities within HHS, with the National Institutes of Health (NIH) facing the most significant proposed reduction. The NIH, the nation’s premier medical research agency, would see its funding slashed by nearly $18 billion under the President’s plan. This proposed decrease raises questions among researchers and public health advocates about the future of biomedical innovation, disease prevention efforts, and the pace of scientific discovery in the United States.
The Proposed Budget Landscape
The discretionary budget request outlines the administration’s priorities for federal spending outside of mandatory programs like Social Security and Medicare. The $93.8 billion proposed for HHS is a stark departure from previous years, reflecting a broader strategy to curb federal spending. This 26.2 percent year-over-year cut, if enacted, would necessitate significant operational changes and potentially impact the scope and scale of public health initiatives across the country.
Deep Dive into Agency Cuts
Beyond the sweeping reduction proposed for NIH, other vital HHS agencies are also targeted for decreased funding in the FY 2026 request. The Health Resources and Services Administration (HRSA), which focuses on improving health care access for people who are geographically isolated, economically or medically vulnerable, would face a proposed cut of approximately $1.7 billion. HRSA’s programs support community health centers, rural health initiatives, and health workforce development, among others.
The Centers for Disease Control and Prevention (CDC), the nation’s leading public health agency responsible for disease prevention and control, would see its funding reduced by approximately $3.6 billion. Such a cut could impact the CDC’s ability to respond to public health emergencies, track infectious diseases, and implement crucial vaccination and public health education campaigns.
Additionally, the Substance Abuse and Mental Health Services Administration (SAMHSA), which leads federal efforts to improve behavioral health, is slated for a proposed reduction of approximately $1 billion. SAMHSA plays a critical role in addressing the opioid crisis, expanding access to mental health care, and supporting individuals in recovery. A reduction in its budget could hinder efforts to combat the growing mental health and addiction challenges facing the nation.
Congressional Response and Negotiation Context
The President’s budget request serves as a starting point for annual appropriations discussions with Congress. While the President proposes, Congress ultimately disposes. Given the magnitude of the proposed cuts to popular and critical health agencies, the budget is expected to face significant opposition from lawmakers on both sides of the aisle, particularly as budget reconciliation negotiations continue in the House. Reconciliation is a legislative process that allows budgetary measures related to spending, revenues, and the federal debt limit to pass with a simple majority in the Senate, potentially bypassing the filibuster. The ongoing negotiations highlight the complex fiscal environment in which the FY 2026 budget will be debated.
Other Health Sector Developments
The week also saw significant regulatory activity impacting the health sector. The Food and Drug Administration (FDA) on May 2, 2025, released important guidance titled “Recommendations to Reduce the Risk of Transmission of Disease Agents Associated with Sepsis by Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps)”. This document updates previous recommendations for donor eligibility, aiming to enhance the safety of these critical medical products which are used in regenerative medicine, transplantation, and other therapeutic applications. The guidance provides updated criteria for screening potential donors of cells and tissues to minimize the risk of transmitting infectious diseases, including those that can lead to sepsis.
Immigration, Security, and Health Care Intersection
Adding another layer to the week’s health-related news, the Executive Office of the President on April 28, 2025, issued an executive order aimed at reinforcing federal authority over immigration and national security. While primarily focused on immigration enforcement, the order could have indirect effects on the health care landscape, particularly by potentially impacting the eligibility or access to federal benefits in jurisdictions designated as “sanctuary cities.” The interplay between immigration status, federal authority, and access to health care services remains a complex and evolving issue.
As the debate over the FY 2026 budget proposal unfolds and other regulatory and executive actions take effect, the health care sector continues to navigate a landscape shaped by significant policy shifts and fiscal considerations. The proposed cuts to major health agencies are poised to be a central point of contention in the upcoming congressional appropriations process.
